On May 15, 2023, Juno Pharmaceuticals Canada has acquired Omega Laboratories, establishing itself as one of Canada's largest specialty generic injectable businesses with extensive domestic manufacturing capabilities. The acquisition was announced by Mark Mantel, CEO of Juno, who emphasized the strengthened capacity of Juno to enhance drug supply within the Canadian healthcare system. This move is particularly strategic as it leverages Omega's newly opened manufacturing facility, approved by Health Canada and the U.S. FDA, to rapidly introduce a wider range of essential pharmaceuticals.

Over the next four years, Juno aims to introduce over 100 new products across various sectors, including pain management, diabetes, and even animal health, among others. This development comes at a crucial time, addressing Canada's increased vulnerability to global market fluctuations and ongoing drug shortages exacerbated by the pandemic.

Bruce Levins, COO of Juno, highlighted the merger as a fusion of Omega's manufacturing proficiency with Juno's commercial and developmental strengths, positioning the company as a powerful entity in the pharmaceutical industry and signaling an expansion into international markets.

The financial advisor for the deal was Bloom Burton Securities Inc., and Aird & Berlis LLP provided legal counsel to Juno. The transaction value was not disclosed in the announcement.